Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation
Brain Sciences · 12.06.2026 · 16 (6) · 634
DOI: 10.3390/brainsci16060634 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 12.06.2026. Verfasst von Aashray Raj und 11 weiteren Autor:innen. Beteiligte Einrichtung: Government Medical College, Bhavnagar, Gujarat 364001, India. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multiple sclerosis (MS), an autoimmune disease, involves peripheral immune activation followed by CNS inflammation in a compartmentalized manner. Although high-efficacy disease-modifying therapies (HE-DMTs) have been effective in suppressing relapses in MS patients, they fail to effectively target chronic microglial activation and smoldering lesions in MS patients. Bruton’s tyrosine kinase inhibitors (BTKis), which are orally active and capable of crossing the blood–brain barrier, have been found to be effective in modulating B cells and CNS-resident myeloid cells.
Objective
The objective was to assess the efficacy and safety of Bruton’s tyrosine kinase inhibitors in patients with relapsing, secondary, and primary progressive MS.
Methods
We performed a systematic review and meta-analysis according to the Cochrane and PRISMA guidelines (PROSPERO registration number: 1323474). We included randomized controlled trials (RCTs) that assessed fenebrutinib, evobrutinib, or tolebrutinib in adult MS patient populations. The main outcome measures were annualized relapse rate, MRI lesion activity, disability progression (EDSS), and hepatotoxicity. The quality of the included trials was assessed for bias by the RoB2 tool.
Results
Six RCTs with 3616 participants were included. BTK inhibitors significantly reduced ARR compared with control therapy (pooled RR 0.24; 95% CI 0.15–0.39). MRI activity was reduced (mean difference −1.45 new/enlarging T2 lesions; 95% CI −2.08 to −0.82). Disability progression was unchanged in short-term relapsing MS trials. Serious hepatotoxicity was reported in 11.0% of BTKi-treated patients compared with 13.7% of control patients (pooled RR 0.80; 95% CI 0.66–0.96). However, increased transaminase elevations were reported in placebo-controlled trials, which indicates that hepatotoxicity remains a clinically relevant safety concern for the class.
Conclusions
BTK inhibitors reduce inflammatory disease activity in relapsing MS and have emerging efficacy in progressive MS phenotypes; however, continued monitoring for hepatotoxicity is warranted. Optimization of CNS penetrance and pharmacologic selectivity may influence long-term clinical positioning.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Government Medical College, Bhavnagar, Gujarat 364001, India.
- B.J. Medical College, Ahmedabad 380016, India.
- JSS Medical College, Mysore 570015, India.
- Kathmandu Model College, Kathmandu 44600, Nepal.
- College of Medicine, University of Illinois, Peoria, IL 61605, USA.
- Tirunelveli Medical College, Tirunelveli 627011, India.
ORCID-Profile: Aashray Raj, Vansh Patel, Mehak Dang, Praveen Nandha Kumar Pitchan Velammal, Sijin Wen
Zitieren
APA
Raj, A., Patel, V., Dang, M., Kayastha, A., Kagzi, Y., Pitchan Velammal, P. N. K., Agrawal, N., Sharma, K., Hansen, N., Wen, S., Jaiswal, S., & Sriwastava, S. (2026). Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation. Brain Sciences, 16(6), 634. https://doi.org/10.3390/brainsci16060634
Vancouver
Raj A, Patel V, Dang M, Kayastha A, Kagzi Y, Pitchan Velammal PNK, et al. Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation. Brain Sciences. 2026;16(6):634. doi:10.3390/brainsci16060634
BibTeX
@article{Raj2026,
author = {Raj, Aashray and Patel, Vansh and Dang, Mehak and Kayastha, Aken and Kagzi, Yusuf and Pitchan Velammal, Praveen Nandha Kumar and Agrawal, Nidhi and Sharma, Kushagra and Hansen, Nicholas and Wen, Sijin and Jaiswal, Shruti and Sriwastava, Shitiz},
title = {Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {6},
pages = {634},
doi = {10.3390/brainsci16060634}
}
EUVIMED